Background: Pulmonary hypertension is a progressive and often fatal complication of the
scleroderma spectrum of disease for which no treatment has been proven effective in a …

This randomized, double-blind, placebo-controlled study of fluticasone propionate aqueous
nasal spray (at a maximum recommended dose of 200 μg each day) administered daily for …

Background The safe and appropriate use of long-acting beta-agonists (LABAs) for the
treatment of asthma has been widely debated. In two large clinical trials, investigators found a …

Background Long-acting beta-agonists (LABAs) have been shown to increase the risk of
asthma-related death among adults and the risk of asthma-related hospitalization among …

Objective. Pulmonary arterial hypertension (PAH) remains challenging to treat, especially in
association with scleroderma. We examined survival rates among patients with PAH in …

Introduction. Fluticasone propionate aqueous nasal spray, a new topical corticosteroid
preparation, is effective when given as 200 µg once daily in patients (> 12 years of age) with …

Background: Fluticasone propionate is a glucocorticoid with negligible oral bioavailability
and very low intranasal bioavailability that is used as an intranasal spray for the treatment of …

Fluticasone propionate was compared with beclomethasone dipropionate for the treatment
of allergic rhinitis in a multicenter, double-blind, randomized, placebo-controlled study during …

Fluticasone propionate (FP) administered via metered-dose inhaler is a potent corticosteroid
effective in the treatment of asthma. To evaluate the efficacy and safety of FP powder …

BACKGROUND: Exacerbations are a major risk and a cause of asthma morbidity and healthcare
utilization. Viral-induced upper respiratory tract infections are the most frequent trigger …